BioSpace News Archive

Cytokinetics, Incorporated today announced that COURAGE-ALS (Clinical Outcomes Using Reldesemtiv on ALSFRS-R in a Global Evaluation in ALS), a Phase 3 clinical trial of reldesemtiv in patients with amyotrophic lateral sclerosis (ALS), is open to enrollment.

Todos Medical, Ltd. today announced that it has made the final payment of $1.25 million to complete its $10 million acquisition of Provista Diagnostics, Inc.

FDA agreed that Galmed can proceed with its proposed clinical studies with Aramchol meglumine in lieu of Aramchol free acid without the need to repeat nonclinical and clinical studies.

Addex Therapeutics Ltd, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021.

Addex Therapeutics Ltd, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced the appointment of Mikhail Kalinichev, PhD, as Head of Translational Science.

Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced that company management will participate in three upcoming virtual investor conferences in August.

Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, provided an update on ongoing antiviral research of Brilacidin, the Company’s defensin-mimetic drug candidate being developed for treatment of COVID-19 under FDA Fast Track designation, by different groups of scientists.

Zentera Therapeutics, a clinical-stage biopharmaceutical company with headquarters in Shanghai, China, announced the successful completion of a $75 million Series B financing.

Autolus Therapeutics plc announced an agreement with Moderna, a biotechnology company pioneering messenger RNA therapeutics and vaccines, granting Moderna an exclusive license to develop and commercialize mRNA therapeutics incorporating Autolus’ proprietary binders for up to four immuno-oncology targets.

Amicus Therapeutics, a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, announced the European Commission has approved Galafold® for use in adolescents aged 12 to <16 years weighing ≥ 45 kg with a confirmed diagnosis of Fabry disease and who have an amenable mutation.